OncoSec Medical Incorporated (ONCSQ) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, OncoSec Medical Incorporated (ONCSQ) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 52/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026OncoSec Medical Incorporated (ONCSQ) Resumen de Asistencia Médica y Tuberías
OncoSec Medical Incorporated, an immuno-oncology company, focused on intra-tumoral DNA-based therapeutics to stimulate anti-tumor immune responses. Despite clinical trial collaborations with Merck and Duke University, the company filed for Chapter 7 liquidation in 2023, impacting its pipeline of cancer treatments and COVID-19 therapies. The company's stock trades on the OTC market.
Tesis de Inversión
OncoSec Medical Incorporated's Chapter 7 liquidation filing in June 2023 represents a significant event for investors. The company's pipeline, which included multiple Phase 1 and Phase 2 clinical trials, is now subject to the bankruptcy proceedings. Key collaborations with Merck and Duke University are unlikely to continue. The company's market capitalization was $0.00B prior to liquidation. The high beta of 9.96 indicates extreme volatility, which is now largely irrelevant given the bankruptcy. Investors should be aware that recovery on OTC stocks after bankruptcy is highly uncertain.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
- The company's market capitalization was $0.00B prior to liquidation.
- The company's pipeline included multiple Phase 1 and Phase 2 clinical trials targeting various cancers and COVID-19.
- OncoSec had clinical trial collaborations with Merck & Co., Inc. and research collaboration with Duke University.
- The stock trades on the OTC market, specifically the OTC Other tier.
Competidores y Pares
Fortalezas
- Proprietary DNA-based therapeutic technology.
- Clinical trial collaborations with established institutions.
- Diverse pipeline of immuno-oncology treatments.
Debilidades
- Chapter 7 liquidation filing.
- Dependence on collaborations for funding.
- High risk of clinical trial failure.
Catalizadores
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
Riesgos
- Ongoing: Chapter 7 bankruptcy proceedings.
- Ongoing: Loss of intellectual property.
- Ongoing: Inability to continue clinical trials.
- Potential: Legal claims from creditors.
- Potential: Delisting from the OTC market.
Oportunidades de crecimiento
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
Oportunidades
- N/A due to liquidation filing.
Amenazas
- Bankruptcy proceedings.
- Loss of intellectual property.
- Inability to continue clinical trials.
Ventajas competitivas
- Proprietary intra-tumoral DNA-based therapeutic technology.
- Clinical trial collaborations with Merck & Co., Inc. and Duke University.
- Pipeline of Phase 1 and Phase 2 clinical trials.
Acerca de ONCSQ
OncoSec Medical Incorporated, formerly known as NetVentory Solutions Inc., was founded in 2008 and rebranded in March 2011 to focus on immuno-oncology. Headquartered in Pennington, New Jersey, the company specialized in designing, developing, and commercializing intra-tumoral DNA-based therapeutics aimed at stimulating and augmenting anti-tumor immune responses for cancer treatment. Their product pipeline included KEYNOTE-695, a Phase 2 trial for advanced melanoma, and TAVO + SARS-CoV-2 spike glycoprotein, a Phase 1 clinical trial for COVID-19. Additional trials included TAVO + epacadostat + pembrolizumab for squamous cell carcinoma of the head and neck, TAVO + nivolumab for breast cancer, and TAVO + CXCL9 for solid tumors, along with OMS-100 and OMS-102 for metastatic melanoma. OncoSec collaborated with Merck & Co., Inc. on KEYNOTE-695 and KEYNOTE-890 and with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination with a HER2-plasmid vaccine. However, on June 14, 2023, OncoSec filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey, ceasing its operations and development programs.
Qué hacen
- Developed intra-tumoral DNA-based therapeutics.
- Focused on stimulating anti-tumor immune responses.
- Conducted Phase 1 and Phase 2 clinical trials for cancer treatments.
- Developed a COVID-19 therapy in Phase 1 clinical trial.
- Collaborated with Merck & Co., Inc. on clinical trials.
- Partnered with Duke University for research.
Modelo de Negocio
- Focused on developing and commercializing immuno-oncology therapeutics.
- Generated revenue through potential future sales of approved therapies.
- Relied on collaborations and partnerships for funding and clinical trials.
Contexto de la Industria
OncoSec Medical Incorporated operated within the competitive biotechnology industry, focusing on immuno-oncology. This sector involves developing therapies that harness the body's immune system to fight cancer. The industry is characterized by high research and development costs, lengthy clinical trial processes, and regulatory hurdles. Companies like OncoSec often collaborate with larger pharmaceutical firms to fund and conduct clinical trials. The failure rate for biotechnology companies is high, and OncoSec's bankruptcy reflects the challenges inherent in bringing novel therapies to market. Competitors focus on similar immuno-oncology approaches, creating a crowded and dynamic landscape.
Clientes Clave
- Patients with advanced melanoma.
- Patients with squamous cell carcinoma of the head and neck.
- Patients with breast cancer.
- Patients with solid tumors.
- Patients with COVID-19.
Finanzas
Gráfico e información
Precio de la acción de OncoSec Medical Incorporated (ONCSQ): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ONCSQ.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ONCSQ.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ONCSQ.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ONCSQ en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Información del mercado OTC de ONCSQ
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to provide current information to the market. These securities often include companies in bankruptcy, those with regulatory issues, or those that are thinly traded. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and limited financial disclosure compared to exchanges like the NYSE or NASDAQ.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure.
- Low liquidity and wide bid-ask spreads.
- Potential for fraud or manipulation.
- Bankruptcy risk.
- Lack of regulatory oversight.
- Verify the company's bankruptcy status with the U.S. Bankruptcy Court.
- Attempt to locate any available financial statements.
- Assess the trading volume and bid-ask spread.
- Consult with a financial advisor.
- Understand the risks associated with OTC Other stocks.
- Determine the potential for recovery in bankruptcy proceedings.
- Research the company's assets and liabilities.
- Prior clinical trial collaborations with Merck & Co., Inc. and Duke University.
- Previous focus on developing immuno-oncology therapies.
- Listing on the OTC market, despite the bankruptcy.
Preguntas Comunes Sobre ONCSQ
¿Cuáles son los factores clave para evaluar ONCSQ?
OncoSec Medical Incorporated (ONCSQ) actualmente tiene una puntuación IA de 52/100, indicando puntuación moderada. Fortaleza clave: Proprietary DNA-based therapeutic technology.. Riesgo principal a monitorear: Ongoing: Chapter 7 bankruptcy proceedings.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ONCSQ?
ONCSQ actualmente puntúa 52/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ONCSQ?
Los precios de ONCSQ se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ONCSQ?
La cobertura de analistas para ONCSQ incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ONCSQ?
Las categorías de riesgo para ONCSQ incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Chapter 7 bankruptcy proceedings.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ONCSQ?
La relación P/E para ONCSQ compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ONCSQ sobrevalorada o infravalorada?
Determinar si OncoSec Medical Incorporated (ONCSQ) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ONCSQ?
OncoSec Medical Incorporated (ONCSQ) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on publicly available sources and may be subject to change due to the ongoing bankruptcy proceedings.